Inherited thrombophilia: Pathogenesis, clinical syndromes, and management

Blood

Volumn 87, Issue 9, 1996, Pages 3531-3544

  De Stefano, Valerio ^a   Finazzi, Guido ^a   Mannucci, Pier Mannuccio ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; ANTIVITAMIN K; HEPARIN; HOMOCYSTEINE; WARFARIN;

ANTICOAGULATION; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG EFFECT; HUMAN; HYPERCOAGULABILITY; POINT MUTATION; PRIORITY JOURNAL; PROTEIN S DEFICIENCY; RECURRENT DISEASE; REVIEW; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 0029876985     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.9.3531.bloodjournal8793531     Document Type: Review

References (138)

1. Egeberg O: Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 13:516, 1965
2. Griffin J, Evatt B, Zimmerman T, Kleiss A, Wideman C: Deficiency of protein C in congenital thrombotic disease. J Clin Invest 68:1370, 1981
3. Comp P, Esmon C: Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 311:1525, 1984
4. Schwarz HP, Fischer M, Hopmeier P, Batard M, Griffin J: Plasma protein S deficiency in familial thrombotic disease. Blood 64:1297, 1984
5. Allaart CF, Briët E: Familial venous thrombophilia, in Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD (eds): Haemostasis and Thrombosis (ed 3). London, UK, Churchill Livingstone, 1994, p 1349
6. Dahlbäck B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 90:1004, 1993
7. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64, 1994
8. Griffin JH, Evatt B, Wideman C, Fernandez JA: Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 82:1989, 1993
9. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM: Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 342:1503, 1993
10. Faioni EM, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci PM: Resistance to activated protein C in nine thrombophilic families: Interference in a protein S functional assay. Thromb Haemost 70:1067, 1993
11. Svensson PJ, Dahlbäck B: Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330:517, 1994
12. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM: High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 14:1080, 1994
13. Lane DA, Caso R: Antithrombin: Structure, genomic organization, function and inherited deficiency, in Tuddenham EGD (ed): The Molecular Biology of Coagulation. Bailliere's Clinical Haematology. London, UK, Bailliere Tindall, 1989, p 961
14. Bjork I, Danielsson A, Fenton JW, Jornwall H: The site in human antithrombin for functional proteolytic cleavage by human thrombin. FEBS Lett 126:257, 1981
15. Bjork I, Olson ST, Shore JD: Molecular mechanisms of the accelerating effect of heparin on the reactions between anti-thrombin and clotting proteinases, in Lane DA, Lindahl U (eds): Heparin: Chemical and Biological Properties, Clinical Applications. London, UK, Edward Arnold, 1989, p 229
16. Blajchman MA, Austin RA, Fernandez-Rachubinski F, Sheffield WP: Molecular basis of inherited human antithrombin deficiency. Blood 80:2159, 1992
17. 1-antitrypsin for the structure and function of serpins. Biochemistry 28:8951, 1989
18. Abildgaard U: Antithrombin and related inhibitors of coagulation, in Poller L (ed): Recent Advances in Blood Coagulation. Edinburgh, UK, Churchill Livingstone, 1981, p 151
19. Rosenberg RD: Actions and interactions of antithrombin and heparin. N Engl J Med 292:146, 1975
20. Tait RC, Walker ID, Perry DJ, Islam SIAM, Daly ME, McCall F, Conkie A, Carrell RW: Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 87:106, 1994
21. Heijboer H, Brandjes DPM, Buller HR, Sturk A, ten Cate JW: Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 323:1512, 1990
22. Tabernero MD, Tomas JF, Alberca I, Orfao A, Borrasca AL, Vicente V: Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol 36:249, 1991
23. Malm J, Laurell M, Nilsson IM, Dahlback B: Thromboembolic disease. Critical evaluation of laboratory investigation. Thromb Haemost 68:7, 1992
24. Pabinger I, Brucker S, Kyrle PA, Schneider B, Korninger H, Niessner H, Lechner K: Hereditary deficiency of antithrombin III, protein C and protein S: Prevalence in patients with a history of venous thrombosis and criteria for rational patient screening. Blood Coagul Fibrinolysis 3:547, 1992
25. Melissari E, Monte G, Lindo VS, Pemberton KD, Wilson NV, Edmondson R, Das S, Kakkar VV: Congenital thrombophilia among patients with venous thromboembolism. Blood Coagul Fibrinolysis 3:749, 1992
26. Lane DA, Olds RJ, Boisclair M, Chowdhury V, Them SL, Cooper DN, Blajchman M, Perry D, Emmerich J, Aiach M: Antithrombin III mutation database: First update. Thromb Haemost 70:361, 1993
27. Erdjument H, Lane DA, Ireland H, Di Marzo V, Panico M, Morris HR, Tripodi A, Mannucci PM: Antithrombin Milano, single amino acid substitution at the reactive site, Arg 393 to Cys. Thromb Haemost 60:471, 1988
28. Lane DA, Erdjument H, Thompson E, Panico M, Di Marzo V, Morris HR, Leone G, De Stefano V, Thein SL: A novel amino acid substitution in the reactive site of a congenital variant antithrombin. Antithrombin Pescara, Arg 393 to Pro caused by CGT to CCT mutation. J Biol Chem 264:10200, 1989
29. Caso R, Lane DA, Thompson EA, Olds RJ, Thein SL, Panico M, Blench I, Morris NR, Freyssinet JM, Aiach M, Rodeghiero F, Finazzi G: Antithrombin Vicenza, Ala 384 to Pro (GCA to CCA) mutation, transforming the inhibitor into a substrate. Br J Haematol 77:87, 1991
30. Lane DA, Olds RJ, Conard J, Boisclair M, Bock SC, Hultin M, Abildgaard V, Ireland H, Thomson E, Sas G, Horellou MH, Tamponi G, Thein SL: Pleiotropic effects of antithrombin strand 1C substitution mutation. J Clin Invest 90:2422, 1992
31. Kisiel W: Human plasma protein C. Isolation, characterization and mechanism of activation by alpha-thrombin. J Clin Invest 64:761, 1979
32. Epstein DJ, Bergum W, Bajaj SP, Rapaport SI: Radioimmunoassays for protein C and factor X. Plasma antigen levels in abnormal hemostatic states. Am J Clin Pathol 82:573, 1984
33. Dahlbäck B: The protein C anticoagulant system: Inherited defects as basis for venous thrombosis. Thromb Res 77:1, 1995
34. Odegaard B, Mann KG: Proteolysis of factor Va by factor Xa and activated protein C. J Biol Chem 262:11233, 1987
35. Kalafatis M, Rand MD, Mann KG: The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 269:31869, 1994
36. Kalafatis M, Bertina RM, Rand MD, Mann KG: Characterization of the molecular defect in factor V R506. J Biol Chem 270:4053, 1995
37. Dahlbäck B: Protein S and C4b-binding protein: Components involved in the regulation of the protein C anticoagulant system. Thromb Haemost 66:49, 1991
38. D'Angelo A, Viganò-D'Angelo S, Esmon CT, Comp PC: Acquired deficiencies of protein S. Protein S activity during oral anticoagulation, liver disease and disseminated intravascular coagulation. J Clin Invest 81:1445, 1988
39. Ohlin AK, Marlar RA: The first mutation identified in the thrombomodulin gene in a 45-year-old man presenting with thromboembolic disease. Blood 85:330, 1995
40. Tuddenham EGD, Cooper DN: Protein C and protein C inhibitor, in Tuddenham EGD, Cooper DN (eds): The Molecular Genetics of Haemostasis and Its Inherited Disorders. New York, NY, Oxford University Press, 1994, p 149
41. Miletich J, Sherman L, Broze G Jr: Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 317:991, 1987
42. Tait RC, Walker ID, Reitsma PH, Islam SIAM, McCall F, Poort SR, Conkie JA, Bertina RM: Prevalence of protein C deficiency in the healthy population. Thromb Haemost 73:87, 1995
43. Briët E, Broekmans AW, Engesser L: Hereditary protein S deficiency, in Bertina RM (ed): Protein C and Related Proteins. Edinburgh, UK, Churchill Livingstone, 1988, p 203
44. Zoller B, Garcia de Frutos P, Dahlbäck B: Evaluation of the relationship between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease. Blood 85:3524, 1995
45. Halbmayer WM, Haushofer A, Schon R, Fischer M: The prevalence of poor anticoagulant response to activated protein C (APC-resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis 5:51, 1994
46. Legnani C, Palareti G, Biagi R, Coccheri S: Evaluation of activated protein C resistance in stored plasma. Lancet 343:1289, 1994
47. Cadroy Y, Siè P, Boneu B: Frequency of a defective response to activated protein C in patients with a history of venous thrombosis. Blood 83:2008, 1994
48. Cushman M, Bhushan F, Bovill E, Tracy R: Plasma resistance to activated protein C in venous and arterial thrombosis. Thromb Haemost 72:647, 1994
49. De Stefano V, Mastrangelo S, Paciaroni K, Ireland H, Lane DA, Scirpa P, Bizzi B, Leone G: Thrombotic risk during pregnancy and puerperium in women with APC-resistance. Effective subcutaneous heparin prophylaxis in a pregnant patient. Thromb Haemostas 74:793, 1995
50. Alhenc-Gelas M, Gandrille S, Aubry ML, Emmerich J, Fiessinger JN, Aiach M: Unexplained thrombosis and factor V Leiden mutation. Lancet 344:555, 1994
51. Voorberg J, Roelse J, Koopman R, Buller H, Berends F, ten Cate JW, Mertens K, van Mourik JA: Association of idiopathic venous thromboembolism with single-point mutation at Arg506 of factor V. Lancet 343:1535, 1994
52. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP: Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 332:912, 1995
53. Rees DC, Cox M, Clegg JB: World distribution of factor V Leiden. Lancet 346:1133, 1995
54. Reitsma PH, Bernardi F, Doig RG, Gandrille S, Greengard JS, Ireland H, Krawczak M, Lind B, Long GL, Poort SR, Saito H, Sala N, Witt I, Cooper DN: Protein C deficiency: A database of mutations, 1995 update Thromb Haemost 73:876, 1995
55. Aiach, M, Gandrille S, Emmerich J: A review of mutations causing deficiencies of antithrombin, protein C and protein S. Thromb Haemost 74:81, 1995
56. Gomez E, Poort SR, Bertina RM, Reitsma PH: Identification of eight point mutations in protein S deficiency type I. Analysis of 15 pedigrees. Thromb Haemost 73:750, 1995
57. Formstone CJ, Wacey AI, Berg L-P, Rahman S, Bevan D, Rowley M, Yoke J, Bernardi F, Legnani C, Simioni P, Girolami A, Tuddenham EGD, Kakkar VV, Cooper DN: Detection and characterization of seven novel protein S (PROS) gene lesions: Evaluation of reverse transcript-polymerase chain reaction as a mutation screening strategy. Blood 86:2632, 1995
58. Mustafa S, Pabinger I, Mannhalter C: Protein S deficiency type I: identification of point mutations in 9 of 10 families. Blood 86:3444, 1995
59. Zoller B, Svensson PJ, He X, Dalhback B: Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 94:2521, 1994
60. Mudd SH, Levy HL, Skovby F: Disorders of transulfuration, in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic Basis of Inherited Disease New York, NY, McGraw-Hill, 1989, p 693
61. Malinov MR: Homocyst(e)ine and arterial occlusive diseases. J Int Med 236:603, 1994
62. Naurath JH, Joosten E, Riezler R, Stabler SP, Allen RH, Lindenbaum J: Effects of vitamin B 12, folate and vitamin B6 supplement in elderly people with normal serum vitamin concentration. Lancet 346:85, 1995
63. Harker LA, Ross R, Slichter SJ, Scott CR: Homocystine-induced arteriosclerosis: The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 58:731, 1976
64. Starkebaum G, Harlan JM: Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 77:1370, 1986
65. Hajjar KA: Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 91:2873, 1993
66. Stamler JS, Osborne JA, Jaraki O, Mullins M, Singel D, Loscalzo J: Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 91:308, 1993
67. Wang J, Dudman NPB, Wilken DEL: Effects of homocysteine and related compounds on prostacyclin production by cultured human vascular endothelial cells. Thromb Haemost 70:1047, 1993
68. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM: Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 13:1327, 1993
69. Nishinaga M, Ozawa T, Shimada K: Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aorlic endothelial cells. J Clin Invest 92:1381, 1993
70. Broekmans AW, Conard J: Hereditary protein C deficiency, in Bertina RM (ed): Protein C and Related Proteins. Edinburgh, UK, Churchill Livingstone, 1988, p 160
71. Demers C, Ginsberg JS, Hirsh J, Henderson P, Blajchman MA: Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. Ann Intern Med 116:754, 1992
72. De Stefano V, Leone G, Mastrangelo S, Tripodi A, Rodeghiero F, Castaman G, Barbui T, Finazzi G, Bizzi B, Mannucci PM: Clinical manifestations and management of inherited thrombophilia: Retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 72:352, 1994
73. Martinelli I, Faioni EM, Monzani ML, Mannucci PM: inherited resistance to activated protein C (APC): Clinical and laboratory features. Blood 84:84a, 1994 (abstr, suppl 1)
74. Finazzi G, Barbui T: Different incidence of venous thrombosis in patients with inherited deficiencies of antithrombin III, protein C and protein S. Thromb Haemost 71:15, 1994
75. Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM: Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient patients. Blood 84:1031, 1994
76. Zoller B, Bernsdotter A, Garcia de Frutos P, Dahlbäck B: Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 85:3518, 1995
77. Ireland H, Bayslon TA, Chowdhury V, Thein SL, Conard J, Pabinger I, Lane DA: Factor V Leiden as an indipendent risk factor for thrombosis in antithrombin deficiency type II: Heparin binding site. Thromb Haemost 73:1361, 1995
78. Conard J, Horellou MH, Van Dreden P, Lecompte T, Samama M: Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: Study of 78 women. Thromb Haemost 63:319, 1990
79. De Stefano V, Leone G, Mastrangelo S, Tripodi A, Rodeghiero F, Castaman G, Barbui T, Finazzi G, Bizzi B, Mannucci PM: Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III. protein C, protein S. Thromb Haemost 71:799, 1994
80. Vicente V, Rodriguez C, Soto I, Fernandez M, Moraleda JM: Risk of thrombosis during pregnancy and post-partum in hereditary thrombophilia. Am J Hematol 46:151, 1994
81. Pabinger I, Schneider B, and the GTH Group on Natural Inhibitors: Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. Thromb Haemost 71:548, 1994
82. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR: Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 344:1453, 1994
83. Finazzi G, Caccia R, Barbui T: Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: Review of 404 cases. Thromb Haemost 58:1094, 1987
84. Chowdury V, Lane DA, Mille B, Auberger K, Gandenberger-Bachem S, Pabinger I, Olds RJ, Thein SL: Homozygous antithrombin deficiency: Report of two new cases (99Leu to Phe) associated with arterial and venous thrombosis. Thromb Haemost 72:198, 1994
85. Hakten M, Deniz U, Ozbay G, Ulutin ON: Two cases of homozygous antithrombin III deficiency in a family with congenital deficiency of AT, in Senzinger H, Vinazzer H (eds): Thrombosis and Haemorrhagic Disorders. Wurzburg, Germany, Schmitt and Meyer GmbH, 1989, p 177
86. Branson HE, Katz J, Marble R, Griffin JH: Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminant, in a newborn infant. Lancet 2:1165, 1983
87. Marlar RA, Montgomery RR, Madden RM: Homozygous protein C deficiency, in Bertina RM (ed): Protein C and Related Proteins. Edinburgh, UK, Churchill Livingstone, 1988, p 182
88. Tripodi A, Franchi F, Krachmalnicoff A, Mannucci PM: Asymptomatic homozygous protein C deficiency. Acta Haematol 83-152, 1990
89. Sharon C, Tirindelli MC, Mannucci PM, Tripodi A, Mariani G: Homozygous protein C deficiency with moderately severe clinical symptoms. Thromb Res 41:483, 1986
90. Mahasandana C, Suvatte V, Marlar RA, Manco-Johnson M, Jacobson LJ, Hathaway WE: Neonatal purpura fulminans associated with homozygous protein S deficiency. Lancet 335:61, 1990
91. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH: High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85:1504, 1995
92. Holm J, Zoller R, Svensson PJ, Berntrop E, Erhardt L, Dahlbäck B: Myocardial infarction associated with homozygous resistance to activated protein C. Lancet 344:952, 1994
93. Selhub J, Jacques PF, Boston AG, D'Agostino RB, Wilson PWF, Belanger AJ, O'Leary DH, Wolf PA, Schaeffer EJ, Rosemberg IH: Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 332:286, 1995
94. Den Heijer M, Blom HJ, Gerrits WBJ, Rosendaal FR, Haak HL, Wijermans PW, Bos GMJ: Is hyperhomocysteinaemia a risk factor for venous thrombosis? Lancet 345:882, 1995
95. Den Heijer M, Koster T, Blom HJ, Bos GMJ, Briet E, Reitsma P, Vandenbroucke JP, Rosendaal FR: Hyperhomocystememia as a risk factor for deep vein thrombosis. N Engl J Med 334:759, 1996
96. Berg K, Malinow R, Kierluf P, Upson B: Population variation and genetics of plasma homocyst(e)ine levels. Clin Genet 41:315, 1992
97. Odegard OR, Lie M, Abildgaard U: Heparin cofactor activity measured with an amidolytic method. Thromb Res 6:287, 1975
98. van Voorthuizen H, Kluft C: Improved assay conditions for automated antithrombin III determination with the chromogenic substrate S-2238. Thromb Haemost 52:350, 1984
99. Mannucci PM, Boyer C, Tripodi A, Viganò-D'Angelo S, Wolf M, Valsecchi C, D'Angelo A, Meyer D, Larrieu MJ: Multicenter comparison of five functional and two immunological assays for protein C. Thromb Haemost 57:44, 1987
100. Ireland H, Bayston T, Thomson E, Adami A, Youclav C, Lane DA, Finazzi G, Barbui T: Apparent heterozygous type II protein C deficiency caused by the factor V 506Arg to Gln mutation. Thromb Haemost 73:727, 1995
101. Martar RA, Adcock DM, Madden RM: Hereditary dysfunctional protein C molecules (type II). Assay characterization and proposed classification. Thromb Haemost 63:375, 1990
102. Suzuki K, Nishioka J: Plasma protein S activity measured using protac, a snake-venom derived activator of protein C. Thromb Res 49:241, 1988
103. Wolf M, Boyer-Neumann C, Martinoli JL, Leroy-Matheron C, Amiral C, Meyer D, Larrieu MJ: A new functional assay for human protein S activity using activated factor V as substrate. Thromb Haemost 62:1144, 1989
104. Preda L, Tripodi A, Valsecchi C, Lombardi A, Finotto E, Mannucci PM: A prothrombin time-based functional assay of protein S. Thromb Res 60:19, 1990
105. Boyer-Neumann C, Bertina RM, Tripodi A, D'Angelo A, Wolf M, Viganò-D'Angelo S, Mannucci PM, Meyer D, Larrieu MJ: Comparison of functional assays for protein S. European collaborative study of patients with congenital and acquired deficiency. Thromb Haemost 70:946, 1993
106. Cooper PC, Hampton KK, Makris M, Abuzenadah A, Paul B, Preston FE: Further evidence that activated protein C resistance can be misdiagnosed as inherited functional protein S deficiency. Br J Haematol 88:201, 1994
107. Faioni EM, Boyer-Neumann C, Franchi F, Wolf M, Meyer D, Mannucci PM: Another protein S functional assays is sensitive to resistance to activated protein C. Thromb Haemost 72:643, 1994
108. Tripodi A, Bertina RM, Conard J, Pabinger I, Sala N, Mannucci PM: Multicenter evaluation of three commercial methods for measuring protein S antigen. Thromb Haemost 68:149, 1992
109. Malm J, Laurell M, Dahlback B: Changes in the plasma levels of vitamin K-dependent proteins C and S and of C4b-binding protein during pregnancy and oral contraception. Br J Haematol 68:437, 1988
110. Wolf M, Boyer-Neumann C, Peynaud-Deboyle E, Marfaring-Koka A, Amiral J, Meyer D: Clinical applications of a direct assay of free protein S antigen using monoclonal antibodies. A study of 59 cases. Blood Coagul Fibrinolysis 5:187, 1994
111. Rosen S, Johansson K, Lindberg K, Dahlbäck B (for the APC resistance study group). Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasma from healthy individuals. Thromb Haemost 72:255, 1994
112. de Ronde H, Bertina R: Laboratory diagnosis of APC-resistance: A critical evaluation of the test and development of diagnostic criteria. Thromb Haemost 72:880, 1994
113. 506 to Gln mutation in the factor V gene, and venous thrombosis. Thromb Haemost 73:739, 1995
114. Boers GHJ, Fowler B, Smals AGH: Improved identification of heterozygotes for homocystinuria due to cystathionine synthase deficiency in cultured fibroblasts. Hum Genet 69:164, 1985
115. Goyette P, Frosst P, Rosenblatt DS, Rozen R: Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype-phenotype correlations in severe metylenetetrahydrofolate reductase deficiency. Am J Hum Genet 56:1052, 1995
116. De Franchis R, Kozich V, McInnes RR, Kraus JP: Identical genotypes in siblings with different homocystinuric phenotypes: Identification of three mutations in cystathionine β-synthase using an improved bacterial expression system. Hum Mol Genet 3:1103, 1994
117. Rosendaal FR, Heijboer H, Briët E, Buller HR, Brandjes DPM, De Bruin K, Hommes DW, Vandenbroucke JP: Mortality in inherited antithrombin III deficiency 1830 to 1989. Lancet 337:260, 1991
118. Allart CF, Rosendaal FR, Noteboom WMP, Briët E: No excess mortality in heterozygotes for hereditary protein C deficiency type I-1820 to 1993. Thromb Haemost 73:1252, 1995
119. Mannucci PM, Boyer C, Wolf M, Tripodi A, Larrieu MJ: Treatment of congenital antithrombin III deficiency with concentrates. Br J Haematol 50:531, 1982
120. Schwartz RS, Bauer KA, Rosenberg RD, Kavanaugh EJ, Davies DC, Bogdanoff DA: Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. Am J Med 87:53, 1989 (suppl 3B)
121. Menache D, O'Malley JP, Schorr JB, Wagner B, Williams C, and the Cooperative Study Group: Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Blood 75:33, 1990
122. De Stefano V, Mastrangelo S, Schwarz HP, Bizzi B, Leone G: Replacement therapy with purified concentrate of protein C in homozygous and heterozygous patients. Thromb Haemost 69:1254, 1993
123. Brandt P, Stenbjerg S. Subcutaneous heparin for thrombosis in pregnant women with hereditary antithrombin III deficiency. Lancet 1:100, 1979
124. Samson D, Stirling Y, Wolf L, Howarth D, Seghatchian MJ, De Chazal R: Management of planned pregnancy in a patient with congenital antithrombin III deficiency. Br J Haematol 56:243, 1984
125. Michiels JJ, Stibbe J, Vellenga E, van Vliet HHDM: Prophylaxis of thrombosis in antithrombin III-deficient women during pregnancy and delivery. Eur J Obstet Gynecol Reprod Biol 18:149, 1984
126. De Stefano V, Leone G, De Carolis S, Ferrelli R, Di Donfrancesco A, Moneta E, Bizzi B: Management of pregnancy in women with antithrombin III congenital defect: Report of four cases. Thromb Haemost 59:193, 1988
127. Pabinger I, Kyrle PA, Heistinger M, Eichinger S, Wittmann E, Lechner K: The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: A prospective cohort study. Thromb Haemost 71:441, 1994
128. Hellgren M, Tengborn L, Abildgaard U: Pregnancy in women with congenital antithrombin III deficiency: Experience of treatment with heparin and antilhrombin. Gynecol Obstet Invest 14:127, 1982
129. Manco-Johnson M, Nuss R. Protein C concentrate prevents peripartum thrombosis. Am J Haematol 40:69, 1992
130. Bauer KA: Management of patients with hereditary defects predisposing to thrombosis including pregnant women. Thromb Haemost 74:94, 1995
131. Finazzi G, Barbui T, and the ad hoc Study Group: A retrospective study on oral anticoagulant prophylaxis in 103 Italian patients with hereditary thrombophilia and thrombosis. Res Clin Lab 20:245, 1990
132. Michiels JJ, Stibbe J, Bertina R, Broekmans A: Effectiveness of long term oral anticoagulation treatment in preventing venous thrombosis in hereditary protein S deficiency. Br Med J 295:641, 1987
133. Schulman S, Tengborn L: Treatment of venous thromboembolism in patients with congenital deficiency of antithrombin III. Thromb Haemost 68:634, 1992
134. Samama M, Horellou MH, Soria J, Conard J, Nicolas G: Successful progressive anticoagulation in a severe protein C deficiency and previous skin necrosis at the initiation of oral anticoagulant treatment. Thromb Haemost 51:132, 1984
135. De Stefano V, Mastrangelo S, Schwarz HP, Pola P, Flore R, Bizzi B, Leone G: Replacement therapy with a purified protein C concentrate during initiation of oral anticoagulation in severe protein C congenital deficiency. Thromb Haemost 70:247, 1993
136. Marlar RA, Montgomery RR, Broekmans AW: Report on the diagnosis and treatment of homozygous protein C deficiency. Thromb Haemost 61:529, 1989
137. Dreyfus M, Magny FJ, Bridey F, Schwarz HP, Planchi C, Dehan M, Tcherma G: Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med 325:1565, 1991
138. Bertina RM, Reitsma PM, Rosendaal FR, Vandenbroucke JP: Resistance to activated protein C and Factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 74:449, 1995